Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/23/2018 |
| Start Date: | September 2008 |
| End Date: | February 2019 |
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma
The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track
tumor growth for renal cell carcinoma while the participant is receiving clinical treatment
therapy with sunitinib or pazopanib. An MRI is a sophisticated type of scan that uses
powerful magnets to make clearer images or to focus on detailed medical information in the
participants abdomen and pelvis. This imaging done for this study will use the ASL MRI
technique that allows us to see blood flow changes which possibly may indicated tumor growth.
tumor growth for renal cell carcinoma while the participant is receiving clinical treatment
therapy with sunitinib or pazopanib. An MRI is a sophisticated type of scan that uses
powerful magnets to make clearer images or to focus on detailed medical information in the
participants abdomen and pelvis. This imaging done for this study will use the ASL MRI
technique that allows us to see blood flow changes which possibly may indicated tumor growth.
- MRI's will be performed at specific time points during the participants treatment for
renal cell carcinoma with the drug sunitinib or pazopanib. These ASL MRI's will be
performed at baseline, 2 weeks upon initiation of therapy with sunitinib/pazopanib,
after cycle 2 and/or cycle 4 of therapy, and at the end of therapy.
- The MRI tests for all participants will be done at Beth Israel Deaconess Medical Center.
renal cell carcinoma with the drug sunitinib or pazopanib. These ASL MRI's will be
performed at baseline, 2 weeks upon initiation of therapy with sunitinib/pazopanib,
after cycle 2 and/or cycle 4 of therapy, and at the end of therapy.
- The MRI tests for all participants will be done at Beth Israel Deaconess Medical Center.
Inclusion Criteria:
- Patients diagnosed with metastatic renal cell carcinoma and who will initiate
sunitinib or pazopanib
- Enrolled on protocol 06-105, "Collection of specimens and clinical data from patients
with renal cell carcinoma treated with targeted therapies," or receiving Pazopanib as
part of routine clinical care.
- Found to have tumors that are 2.5cm or greater as determined by CT imaging
- Candidate lesions for ASL MRI should be 2.5cm or greater. Order of preference of
lesion location will be as follows: abdominal lesions, bone lesions and chest lesions
Exclusion Criteria:
- Contraindication to MRI
We found this trial at
2
sites
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials